Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 1999

View Archived Issues

Licensing opportunity from NIH: novel acyltriazene antitumor agents

TxA2 synthase inhibitor may have application in SAH

Bioniche completes merger to create Bioniche Life Sciences

Growth hormone tested in HIV-positive patients with opportunistic infections

Company Profile: Intracel

Selective glucocorticoid receptor modulators codeveloped by Abbott, Ligand

Searle claims wide series of new CETP inhibitors for hyperlipidemic conditions

Novel pyridine and pyrimidine derivatives from Amgen particularly useful for obesity Rx

Antiproliferative agents and protein farnesyltransferase inhibitors designed at RPR

Georgetown U discloses new classes of neuroprotective compounds

Pyrimidine derivatives from Tularik useful for CMV infections

FIP '99: complexes of NO donor with improved physicochemical and pharmacological properties

Sublingual nicotine tablets as alternative to Nicorette gum: clinical results reported at FIP '99

Favorable pharmacokinetics and pharmacodynamics reported for insulin aspart at FIP '99

Valentis and PolyMASC finalize merger

FibroGen and Taisho to collaborate on kidney fibrosis research

Onyx to initiate phase III trial with ONYX-015 in treatment of head and neck cancer

Kirin Brewery reports SAR in the area of Fas/FAP-1 binding inhibitors

D-Pharm's valproic acid derivative completes safety studies

MGI Pharma begins to copromote Azulfidine EN-tabs in RA

Imaging agent NeoTect available in U.S. for lung cancer diagnosis

Novel antibiotics targeting bacterial cell wall biosynthesis synthesized by Incara

Micrologix Biotech receives fast track designation for antimicrobial product

Rhone-Poulenc to proceed with complete divestment of participation in Rhodia

More on Hughes Institute's new anti-HIV compounds with efficacy against resistant strains

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...